|

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

RECRUITINGPhase 2Sponsored by Hunan Province Tumor Hospital
Actively Recruiting
PhasePhase 2
SponsorHunan Province Tumor Hospital
Started2022-12-25
Est. completion2025-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05584267

Summary

This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years of age on day of signing informed consent
* Histopathology confirmed non-small cell lung cancer
* Asymptomatic brain metastases
* EGFR/ALK ROS1 driver gene mutation negative
* RECIST 1.1 based available assessment of lesions
* ECOG 0-1
* Brain metastases 1-4
* Single lesion ≤4cm

Exclusion Criteria:

* Patients with contraindication of chemotherapy Pregnant or breast feeding women

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.